All Updates

All Updates

icon
Filter
Partnerships
Insilico Medicine enters license collaboration with Exelixis for AI-generated cancer diagnosis
AI Drug Discovery
Sep 12, 2023
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
AI Drug Discovery

AI Drug Discovery

Sep 12, 2023

Insilico Medicine enters license collaboration with Exelixis for AI-generated cancer diagnosis

Partnerships

  • Hong Kong-based AI drug discovery company Insilico Medicine and Pharmaceutical company Exelixis has entered an exclusive license agreement for the development and commercialization of an AI-generated cancer treatment, ISM3091.

  • Under the terms of the license agreement, Exelixis will pay an upfront fee of USD 80 million to Insilico in the third quarter of 2023 and also make future milestone payments and royalties based on the development and commercial success of ISM3091.

  • The partnership will allow Exelixis to obtain global rights to ISM3091, a small molecule that targets USP1, and offer a differentiated treatment for BRCA-mutated tumors. Additionally, Exelixis aims to accelerate Phase I trial enrollment for ISM3091 through this collaboration. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.